Matter Bio: Pioneering Longevity Through Genomic Integrity

Matter Bio is a longevity company committed to treating the diseases of aging by protecting cells from DNA damage and removing cells that have accumulated too much damage (e.g. cancer).

Drawing inspiration from the information theory of aging, we posit that age-related diseases—and possibly aging itself—result from the accumulated loss of DNA integrity due to damage.

As we age, our genomes accrue damage from both external and internal sources at a roughly linear rate. While cells possess powerful DNA repair mechanisms, these systems are not infallible. Errors can be missed, leading to mutations, structural variations, epigenetic drift, and other forms of information loss. This accumulation triggers a cascade of problems that culminate in age-related diseases.

Nature's Blueprint for Longevity

Research into extreme longevity across various species reveals a consistent pattern: longer-lived animals exhibit superior genome stability and DNA repair capabilities compared to their shorter-lived counterparts. This not only leads to longer life, but also to drastically reduced incidence of cancer and other diseases of aging.

This phenomenon has been observed across many species such as naked mole rats, rockfish, bowhead whales, Greenland sharks, and even supercentenarian humans.

At Matter, we aim to harness these naturally occurring DNA stability variants and deliver them to human cells to dramatically enhance cellular longevity. When cancer is already present, we delivery an engineered bacteria to find and kill tumor cells, wherever they are.

Our Pipeline

• Revenue-Generating ecNGS Sequencing: Providing cutting-edge sequencing services to understand genomic alterations with unprecedented accuracy.
• Clinical-Stage Solid Tumor Program: Entering Phase 1 clinical trials to target and remove cancerous cells.
• Pre-Clinical DNA Repair Program: Developing therapies to repair or replace damaged genes associated with aging and disease.

Our Team